Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesEpigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features
Molecular Carcinogenesis, 06/30/09
Kim DS et al. - In a trial to explore the role of Homeobox A5 (HOXA5) in non-small cell lung cancer (NSCLC), it was shown that downregulation of the HOXA5 gene by aberrant promoter methylation occurs in the vast majority of NSCLCs and it may play a role in the pathogenesis of NSCLC.
Methods- Methylation status of the promoter region of the HOXA5 gene was investigated in NSCLCs using nested and standard methylation-specific PCR (MSP).
- Methylation status with clinicopathological features was correlated.
- With standard MSP analysis, HOXA5 methylation was found in 113 (81.3%) of 139 NSCLCs and 72 (51.8%) in their corresponding nonmalignant lung tissues.
- RT-PCR and immunohistochemical analysis showed that HOXA5 methylation correlates with gene expression.
- In pts with stage I disease, HOXA5 methylation was more frequent in smokers than in never-smokes.
- There was no influence of HOXA5 methylation on survival in all NSCLCs or at stages II-IV.
- In patients with stage I disease, HOXA5 methylation was associated with a borderline significantly worse survival.
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Serum calcium levels are elevated among women with untreated postmenopausal breast cancer
Cancer Causes and Control, 11/03/09
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
Journal of Clinical Oncology, 10/29/09
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
Lung Cancer, 11/03/09
Sponsor
Article Search
Sponsor
Sponsor